[Hormonal therapy of menopause: 2004 position of the Department of Female Endocrinology and Andrology of the Brazilian Society of Endocrinology and Metabolism].
After randomized clinical trials produced impact and questions at the medical community on menopause hormonal therapy (MHT), the Department of Female Endocrinology and Andrology of the Brazilian Society of Endocrinology convened a group of specialists to produce an informative, critical and position paper, offering guidelines for those who practice or are called to express their opinion on menopause therapy. MHT is indicated for relief of vasomotor symptoms, maintenance of vaginal tropism, bone mass and collagen preservation, sexual and general well-being. Studies on primary cardiovascular prevention are not conclusive, and thus insufficient to indicate or not MHT for this purpose. Schemes and forms of association should de individualized. Whenever possible, one should use 17-beta estradiol, associated to natural progesterone or its derivatives in women with an intact uterus, at the lowest effective doses. Duration of therapy depends on its aims, and should be periodically re-evaluated through an individual indication/contra-indication balance. Orientation toward a healthier lifestyle, with smoking cessation, adequate calcium intake and a low fat diet, together with regular physical activity is fundamental during menopause.
Hospital de Lagoa, Ministério da Saúde. rclapauch@uol.com.br
Ruth
R
Clapauch
Amanda
A
Athayde
Ricardo M R
RM
Meirelles
Rita V
RV
Weiss
Dolores P
DP
Pardini
Lenora Maria C S M
LM
Leão
Lizanka P F
LP
Marinheiro
D001938:Brazil; D019091:Critical Pathways; D004704:Endocrinology; D016021:Epidemiologic Studies; D015914:Estrogen Replacement Therapy; D005260:Female; D020249:Hormone Replacement Therapy / Q000592:standards*; D006801:Humans; D008593:Menopause / Q000502:physiology*; D012955:Societies, Medical; D016387:Women's Health